---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-011193"
form_type: "8-K"
ticker: "TECH"
cik: "0000842023"
company_name: "BIO-TECHNE Corp"
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:59:35.282935+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bio-Techne Q4 adjusted EPS $0.49 vs $0.55 YoY; revenue $306.1M (+2%)

## Summary
- Q4 organic revenue up 1% to $306.1M; FY2024 organic revenue up 1% to $1.2B.
- GAAP EPS $0.25 vs $0.47; adjusted EPS $0.49 vs $0.55.
- Diagnostics & Genomics segment grew 9% organically in Q4.
- FY2024 operating cash flow $299M, up 18% YoY.
- Board declared $0.08 quarterly dividend payable Aug 30, record Aug 19.

## SEC filing metadata
- accession: 0001558370-24-011193
- form_type: 8-K
- ticker: TECH
- cik: 0000842023
- company_name: BIO-TECHNE Corp
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/842023/000155837024011193/0001558370-24-011193-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/842023/000155837024011193/tech-20240807x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-011193
- JSON: https://secwatch.observer/filing/0001558370-24-011193.json
- Plain text: https://secwatch.observer/filing/0001558370-24-011193.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.